1. Sum R, Swaminathan M, Rastogi SK, Piloto O and Cheong I. Beta-hemolytic bacteria selectively trigger liposome lysis, enabling rapid and accurate pathogen detection. ACS Sensors (accepted), 2017.
2. Swaminathan M, Yadav PK, Piloto O, Sjöblom T, and Cheong I. Use of a new Poisson-Binomial semi-metric for Image Classification and Recognition. Pattern Recognition, 63: 384–396, 2016
3. Matheny CJ, Wei MC, Bassik MC, Donnelly AJ, Kampmann M, Iwasaki M, Piloto O, Solow-Cordero DE, Bouley DM, Rau R, Brown P, McManus MT, Weissman JS, and Cleary ML. Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. Cell: Chemistry & Biology 20, 1–12, 2013.
4. Zheng R, Bailey E, Nguyen B, Yang X, Piloto O, Levis M, Small D. Further Activation of FLT3 Mutants by FLT3 Ligand. Oncogene 30(38), 4004-4014, 2011.
5. Wang Z, Sommervaille T, Murphy MJ, Piloto O, Smith K and Cleary ML. Glycogen synthase kinase 3 in MLL leukemia maintenance and targeted therapy. Nature, 455(7217): 1205-1209, 2008.
6. Li L, Piloto O, Nguyen B, Greenberg K, Takamiya K, Racke F, Huso D, Sun L, Small D. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood, 111(7): 3849-3858, 2008.
7. Kim K, Baird K, Davis S, Levis M, Piloto O, Li L, Chen P, Meltzer P, Small D. Constitutive FLT3 activation results in specific changes in gene expression in myeloid leukemic cells. Br J Haematol. 138(5): 603-615, 2007.
8. Li L, Piloto O, Ye Z, Kim K, Nguyen B, Yu X, Levis M, Cheng L, Small D. FLT3/ITD expression increases expansion, survival and entry into cell cycle of human hematopoietic stem/progenitor cells. Br J Haematol. 137 (1): 64-75, 2007.
9. Piloto O, Wright M, Brown P, Kim K, Levis M, Small D. Prolonged Exposure to FLT3 Inhibitors leads to Resistance via Activation of Parallel Signaling Pathways. Blood 109(4): 1643-1652, 2007.
10. Piloto O, Nguyen B, Huso D, Kim K, Li Y, Witte L, Hicklin DJ, Brown P, Small D. EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces NOD/SCID engraftment of some ALL cell lines and primary blasts. Cancer Research 66(9): 4843-4851, 2006.
11. Piloto O, Levis M, Huso D, Li Y, Li H, Wang M, Lu D, Wu Y, Bassi R, Balderes P, Zhang H, Ludwig DL, Pytowski B, Kussie P, Bohlen P, Witte L, Zhu Z, Hicklin DJ, Small D. Inhibitory anti-FLT3 mAb are capable of mediating ADCC and reducing engraftment of AML blasts in NOD/SCID mice without reducing engraftment of normal hematopoietic stem cells. Cancer Research 65(4): 1514-1522, 2005.
12. Zheng R, Levis M, Piloto O, Brown P, Baldwin B, Gorin N, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, Small D. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood 103(1): 267-274, 2004.
13. Li Y, Li H, Wang M, Lu D, Wu Y, Bassi R, Balderes P, Zhang H, Ludwig DL, Pytowski B, Kussie P, Piloto O, Small D, Bohlen P, Witte L, Zhu Z, Hicklin DJ. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood 104(4): 1137-1144, 2004.